# Ipamorelin dosing in the published research record

> The doses that have actually appeared in published rodent and human ipamorelin protocols, with half-life, routes, and the chronic-exposure gap clearly drawn. Research context only.

A ledger of the rodent and human protocols that anchor every ipamorelin dose number in circulation — and a clear note on the dosing questions the record does not answer.

## A note on what this page is

This page describes the doses ipamorelin has been administered at in published research protocols. It does not recommend a dose for any human use. Ipamorelin is not approved for human consumption [5]; the only documented human exposure in a registered clinical trial used the intravenous route in a perioperative setting [3]. Subcutaneous dosing in non-clinical use sits outside any approved pathway, and the chronic safety questions that would be required to evaluate it have never been answered in any published human study [4].

Every dose figure below is reported with the species, route, duration, and study citation that produced it. The point of laying them out together is to show what the literature is — a series of short, narrowly-scoped protocols, mostly in rodents, that together do not add up to a chronic human safety database.

## Human intravenous doses (the entire registered record)

Two registered human-dosing protocols dominate the published human ipamorelin literature.

Gobburu et al., 1999 (PK/PD characterization): five escalating fifteen-minute IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, given to eight healthy male volunteers per dose group [2]. Reported terminal plasma half-life approximately two hours; GH peak roughly 0.67 hours after dosing; rapid exponential decline to baseline within hours. Reported as tolerated at every dose level — but in eight men per group, single dose only.

Beck et al., 2014 (Phase 2 RCT in postoperative ileus): 0.03 mg/kg IV ipamorelin twice daily for up to seven days, against placebo, in 114 adults recovering from open or laparoscopic bowel resection [3]. Treatment-emergent adverse events occurred in 87.5 percent of the ipamorelin arm versus 94.8 percent of placebo. Primary efficacy endpoint missed. The trial is the longest registered human exposure to ipamorelin in the published record — seven days, IV, in a perioperative setting [3]. A second Helsinn-sponsored Phase 2 study (NCT01280344) completed but did not lead to a regulatory submission [4]. No human study of subcutaneous ipamorelin appears in the registered record.

## Rodent subcutaneous and intravenous doses

The rodent literature is broader and shorter-window than the human literature. Notable published protocols include:

Johansen et al., 1999: 18, 90, and 450 micrograms per day, divided three times per day, subcutaneously, for 15 days in adult female Sprague-Dawley rats. Outcome: dose-dependent increase in longitudinal bone growth rate from 42 microns per day in vehicle to 44, 50, and 52 microns per day at the three dose levels, P<0.0001. Total IGF-1 unchanged at the timepoints measured [15].

Lall et al., 2003: chronic SC ipamorelin in young female rats; specific dose not fully extractable from the abstract. Outcome: body weight gain and sustained in-vitro GH release from cultured pituitary cells of treated animals, suggesting minimal tachyphylaxis in this model and dosing pattern [16].

Adeghate and Ponery, 2004: in-vitro pancreatic tissue from normal and streptozotocin-diabetic rats incubated with ipamorelin at concentrations from 10^-12 to 10^-6 M. Outcome: direct insulinotropic activity attenuated by L-type calcium channel block, alpha-2-adrenergic block, and a cholinergic-adrenergic blocker cocktail [9].

Tu et al., 2024: intraperitoneal ipamorelin in ferrets; specific dose not fully specified in the abstract. Outcome: reduction in delayed-phase cisplatin-induced weight loss by approximately 24 percent versus control over a 72-hour window, with no effect on cisplatin-induced emesis [13].

## Half-life and pharmacokinetic notes

The terminal plasma half-life of ipamorelin in healthy male volunteers receiving a fifteen-minute IV infusion was approximately two hours [2]. Clearance was 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg, SC50 for half-maximal GH stimulation 214 nmol/L [2]. GH peaked at roughly 0.67 hours after dosing and declined exponentially toward baseline within hours. This is the only published human PK/PD model. SC pharmacokinetics in humans have not been characterized in any registered ipamorelin trial.

The two-hour half-life and short GH peak window are the basis for the intermittent multi-daily dosing patterns that appear in rodent protocols [15][16] and in non-clinical use discussions in review literature. The mechanistic rationale is to approximate the body's natural pulsatile GH release pattern rather than to produce a continuous receptor-occupancy signal, which is the dosing pattern that has been associated with tachyphylaxis in the broader ghrelin-agonist class [16]. Whether intermittent SC ipamorelin dosing avoids tachyphylaxis in chronic human use is an open question.

## Stability, formulation, and the FDA's CMC concerns

Lyophilized ipamorelin is reported stable refrigerated. Reconstituted solutions in laboratory protocols are typically described as having short shelf life. The FDA's October 2024 PCAC review identified two manufacturing-level concerns that sit on top of any dose discussion. The first is aggregation propensity in injectable subcutaneous formulations, which has direct immunogenicity implications [6]. The second is the structural difficulty of impurity characterization given the three unnatural amino acids in the sequence (Aib, D-2-Nal, D-Phe), each of which complicates purification chemistry and chromatographic behavior [6].

These are not dose questions in the pharmacological sense; they are quality questions about the product the dose is delivered in. Forensic analysis of gray-market injectable peptides has documented residual industrial synthesis solvents, heavy metals exceeding pharmaceutical thresholds, and endotoxin levels exceeding safety thresholds in a substantial majority of sampled products [14]. The molecule's intrinsic dose-response is one part of the picture. The vial it arrives in is another part. The two cannot be cleanly separated in any real-world risk assessment.

## References

[2] Gobburu JV et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. Pharmaceutical Research. 1999;16(9):1412-1416.
[3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Phase 2 ipamorelin RCT in postoperative ileus. International Journal of Colorectal Disease. 2014;29(12):1527-1534.
[4] Helsinn Therapeutics (US), Inc. Ipamorelin vs Placebo for Recovery of GI Function. ClinicalTrials.gov NCT01280344. 2014.
[5] U.S. FDA. PCAC Briefing Document (October 29, 2024) — Ipamorelin Acetate / free base review for 503A. 2024.
[6] U.S. FDA / Lexology / Holt Law summaries. FDA Briefing Document on Ipamorelin — aggregation, immunogenicity, unnatural amino acids. 2024.
[9] Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters. 2004;25(6):403-406.
[13] Tu L et al. Anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets. Physiology & Behavior. 2024;284:114631.
[14] Preventive Medicine Daily editorial / pharmacovigilance review. Gray-Market Peptides from China. 2024.
[15] Johansen PB et al. Ipamorelin induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
[16] Lall S et al. Chronic in vivo Ipamorelin treatment in young female rats. Growth Hormone & IGF Research. 2003;13(2-3):126-136.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.